Tyra Biosciences, Inc.
TYRADrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
TYRA Earnings Report
EPS Est: $-0.67 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How TYRA's past catalysts played out
TYRA-300 60mg
Low-grade NMIBC
TYRA-300
Locally Advanced Urothelial Carcinoma
TYRA-300 0.125 mg/kg
Achondroplasia
Dabogratinib (TYRA-300) 60mg
Low Grade Upper Tract Urothelial Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TYRA-300 60mg | Phase 2 | Low-grade NMIBC | - | - |
TYRA-300 | Phase 2 | Locally Advanced Urothelial Carcinoma | - | - |
TYRA-300 0.125 mg/kg | Phase 2 | Achondroplasia | - | - |
Dabogratinib (TYRA-300) 60mg | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Tyra Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Tyra Biosciences, Inc.'s (TYRA) pipeline across Phase 2. Its lead program is TYRA-300 60mg (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tyra Biosciences, Inc.'s next FDA catalyst?→
Tyra Biosciences, Inc.'s (TYRA) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TYRA biotech catalysts?→
Add TYRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tyra Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.